Video

Dr. McCarthy on Eligibility Criteria for Allogeneic BMT

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, explains the factors that determine patient tolerability to allogeneic bone marrow transplant.

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, explains the eligibility criteria he uses to determine patient tolerability to allogeneic bone marrow transplant.

The upper age limit for patients eligible to undergo allogeneic bone marrow transplant has progressed from 50 years to 70 years since the 1980s. Some older patients remain eligible for allogeneic bone marrow transplant because of their overall health and activity, regardless of their age, McCarthy explains.

Patients with underlying kidney, heart or lung disease may not be able to handle the rigors of a transplant. McCarthy says that a 40-year-old with severe cardiac disease will not be an adequate allogeneic transplant candidate whereas a 70-year-old could be, based on comorbidities.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center